Infections with oncogenic types of HPV cause virtually all cases of cervical cancer worldwide. Prophylactic vaccination against HPV 16 and 18, two of the most important HPV types, could protect against a large majority of the cases of cervical cancer globally. Vaccines based on the L1 structural protein of HPV that self-assemble into conformationally-correct virion-like particles (virus-like particles or VLPs) have been shown to be generally safe, immunogenic and effective at preventing precancerous lesions of the cervix associated with HPV-16/18. A community-based Phase 3 randomized controlled trial of an HPV16/18 VLP vaccine was conducted in Costa Rica. Costa Rica was chosen for the Phase 3 trial because of our extensive successful scientific collaborations there, the high risk of cervical cancer, the universal medical system providing national linkage, and the likelihood of very high participation over the many needed years of close clinical follow-up. Randomization and 3-dose vaccination of 7,466 women enrolled into the HPV-16/18 Vaccine Trial in Costa Rica has been successfully completed. Women have been followed actively on an annual or semi-annual basis since enrollment. Women have completed their first four years of follow-up in the trial and have been enrolled in the extended (up to 10 years) follow-up phase of the study. As women complete four years of active follow-up, cross-over vaccination is offered to trial participants, as recommended by the trial Data and Safety Monitoring Board (DSMB) and approved by the Institutional Review Boards (IRBs) overseeing the trial. Results from this study have shown that 1) the vaccine is highly effective at preventing new infections with HPV types 16 or 18, 2) the vaccine confers partial protection against HPV types phylogenetically related to HPV 16 or 18, 3) the vaccine does not help treat existing infections, 4) fewer than 3 doses of the vaccine protects as well as the full 3-dose series for at least 4 years, 5) the vaccine protects against HPV infection at the anus, 6) Vaccine impact declines with increasing age at vaccination, 7) vaccination induces cross-neutralizing potential in sera of vaccinated individuals and 8) modest levels of antibodies generated by natural HPV infection provide partial protection against re-infection. In support of the vaccine trials, a variety of methodologic and ancillary projects are underway or planned, that will maximize the yield of the main effort. This includes evaluation of immunological correlates of protection, including viral neutralization, total type-specific antibodies, and measures of antibody avidity. Immunological correlates of protection among naturally infected women are being examined and studies are underway to better understand why vaccinated women might be protected against HPV types not included in the vaccine formulation. Several analyses are underway or planned to evaluate the natural history of HPV infection at cervical and other sites and of cervical neoplasia in vaccinated and unvaccinated women. This effort is sponsored by Intramural NCI funds and by the NIH Office of Research on Women's Health (ORWH). It was formerly associated with Project Z01 CP010177.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIACP010217-01
Application #
8349608
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2011
Total Cost
$794,804
Indirect Cost
Name
Division of Cancer Epidemiology and Genetics
Department
Type
DUNS #
City
State
Country
Zip Code
Beachler, Daniel C; Tota, Joseph E; Silver, Michelle I et al. (2017) Trends in cervical cancer incidence in younger US women from 2000 to 2013. Gynecol Oncol 144:391-395
Beachler, Daniel C; Lang Kuhs, Krystle A; Struijk, Linda et al. (2017) The Natural History of Oral Human Papillomavirus in Young Costa Rican Women. Sex Transm Dis 44:442-449
Tota, Joseph E; Struyf, Frank; Merikukka, Marko et al. (2017) Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. J Natl Cancer Inst 109:
Beachler, Daniel C; Gonzales, Felisa A; Kobrin, Sarah C et al. (2016) HPV vaccination initiation after the routine-recommended ages of 11-12 in the United States. Papillomavirus Res 2:11-16
Beachler, Daniel C; Jenkins, Gwendolyne; Safaeian, Mahboobeh et al. (2016) Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis. J Infect Dis 213:1444-54
Talarico, Sarah; Safaeian, Mahboobeh; Gonzalez, Paula et al. (2016) Quantitative Detection and Genotyping of Helicobacter pylori from Stool using Droplet Digital PCR Reveals Variation in Bacterial Loads that Correlates with cagA Virulence Gene Carriage. Helicobacter 21:325-33
Hildesheim, Allan; Gonzalez, Paula; Kreimer, Aimee R et al. (2016) Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol 215:212.e1-212.e15
Porras, Carolina; Hildesheim, Allan; González, Paula et al. (2015) Performance of self-collected cervical samples in screening for future precancer using human papillomavirus DNA testing. J Natl Cancer Inst 107:400
Robbins, Hilary A; Waterboer, Tim; Porras, Carolina et al. (2014) Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. Hum Vaccin Immunother 10:2965-74
Hildesheim, Allan; Wacholder, Sholom; Catteau, Gregory et al. (2014) Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 32:5087-97

Showing the most recent 10 out of 17 publications